openPR Logo
Press release

Investigation announced for NASDAQ: MRTX Investors over possible Wrongdoing at Mirati Therapeutics, Inc.

12-01-2021 06:57 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares over potential wrongdoing.

An investigation on behalf of investors in Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares over potential wrongdoing.

Certain directors of Mirati Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties.

Investors who purchased shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Mirati Therapeutics, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

San Diego, CA based Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. Mirati Therapeutics, Inc. reported that its annual Total Revenue rose from $3.33 million in 2019 to $13.39 million in 2020, and that its Net Loss increased from $212.25 million in 2019 to $357.93 million in 2020.

On November 1, 2021, Mirati Therapeutics, Inc, in an SEC filing, disclosed that certain executives would no longer be serving in their positions. In the filing, the Company stated, “

On October 28, 2021, it was determined that Daniel R. Faga would cease serving as the Executive Vice President, Chief Operating Officer and principal financial officer of Mirati Therapeutics, Inc. (the “Company”) and that Joseph Leveque would cease serving as the Company’s Executive Vice President and Chief Medical Officer, effective as of November 1, 2021.”

Shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) declined from $195.99 per share on October 25, 2021, to $134.35 per share on November 24, 2021.

Those who purchased shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for NASDAQ: MRTX Investors over possible Wrongdoing at Mirati Therapeutics, Inc. here

News-ID: 2481995 • Views: 406

More Releases from Shareholders Foundation

Investigation announced for Long-Term Investors in shares of Eargo, Inc. (NASDAQ …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Eargo, Inc.. Investors who are current long term investors in Eargo, Inc. (NASDAQ: EAR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: EAR stocks follows a lawsuit filed against Eargo, Inc. over
eHealth, Inc. (NASDAQ: EHTH) Investor Alert: New Deadline in Lawsuit coming up o …
A new deadline is coming up on March 18, 2022 in the lawsuit that is pending for certain investors in shares of shares of eHealth, Inc. (NASDAQ: EHTH. If you purchased shares of eHealth, Inc. (NASDAQ: EHTH) between April 26, 2018 and July 23, 2020, and / or if you purchased any NASDAQ: EHTH shares prior to April 2018 and continue to hold any of those shares, you have certain options
Investigation announced for Long-Term Investors in shares of BioMarin Pharmaceut …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of BioMarin Pharmaceutical Inc.. Investors who are current long term investors in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: BMRN stocks follows a lawsuit filed against BioMarin
Investigation announced for Investors in shares of Cineplex Inc. (OTC: CPXGF) ov …
An investigation was announced concerning potential securities laws violations by Cineplex Inc. in connection with certain financial statements. Investors who purchased shares of Cineplex Inc. (OTC: CPXGF), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Cineplex Inc. regarding its business, its prospects and its operations were materially false and

All 5 Releases


More Releases for Mirati

Myxoid Round Cell Liposarcoma Drug Market 2020 Emerging Players - Adaptimmune, R …
Myxoid Round Cell Liposarcoma Drug Market Research Report By Therapy (Chemotherapy, Radiation Therapy and Others), Drugs (Trabectedin, Mechlorethamine and Others), Route of Administration (Injectable, Oral), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retailers and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2026 Few of the major competitors currently working in global myxoid round cell
Global Histone Deacetylase Inhibitors Market: Top Investment Pockets in the Mark …
LOS ANGELES, United States: Considering the increasing demand of global market, QY Research as of late produced a research report titled, “Global Histone Deacetylase Inhibitors Market Research Report 2020". The research report speak about the potential development openings that exist in the worldwide market. The report is broken down on the basis of research procedures procured from historical and forecast information. The global Histone Deacetylase Inhibitors market is relied upon
Histone Deacetylase Inhibitors Market Size, Growth, Share Statistics 2020-2026 | …
Histone Deacetylase Inhibitors Market Research Report 2020 is a valuable supply of insightful information for business strategists with Top Countries Data. Histone Deacetylase Inhibitors Market report provides detailed coverage of Histone Deacetylase Inhibitors industry and main market trends. The Histone Deacetylase Inhibitors Market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Histone Deacetylase Inhibitors by geography. Get Sample Copy Of Report
Histone Deacetylase Inhibitors Market Brief Analysis: How the Business Will Grow …
Histone Deacetylase Inhibitors Market 2020 report covers key business segments and wide scope geographies to get deep dive analyzed industry data. The company profiles of top Market players will provide financial analysis listing the company revenue, and market share. The past and present revenue of top players will offer forecast revenue estimates and growth rates. Histone Deacetylase Inhibitors Market research report provide the details about industry overview and analysis about
Histone Deacetylase Inhibitors Market 2020 Growth Projection by Leading Players: …
Global Histone Deacetylase Inhibitors Market Size, Share and Global Trend By Class (Class I HDACs, Class II HDACS, Class III HDACs, Class IV HDACs), Application (Oncology, Neurology), End User (Hospitals, Academic & research institutes, Pharmaceutical companies) and Geography Forecast till 2026. To know How COVID-19 Pandemic Will Impact This Market/Industry -Request a sample copy of the report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/histone-deacetylase-inhibitors-market-100323 Histone Deacetylase Inhibitors Market Key Companies Analyzed: Abcam plc., Cetya Therapeutics, RandD Systems, Inc., Mirati
Trends in Histone Deacetylase Inhibitors Market: Business Analysis 2018-2025 by …
Histone Deacetylase Inhibitors Market Report provides deep analysis about the business module, market size, SWOT analysis, growth opportunities. Top players are Acetylon, Celleron, Chroma, Curis, Mirati, Novartis, Onxeo, Repligen and More. The report focuses on the global Histone Deacetylase Inhibitors market status, future opportunities, growth analysis, key drivers and top players. The study objectives are to present the Histone Deacetylase Inhibitors development in United States, Europe and China. Histone Deacetylase Inhibitors Market